CLINICAL TRIALS PROFILE FOR VALSARTAN

505(b)(2) Clinical Trials for valsartan

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT04047940 ↗	A Study of LY900020 in Healthy Chinese Participants	Completed	Eli Lilly and Company	Phase 1	2019-11-29	This study will evaluate three new formulations of LY900020; a fixed dose, combination drug developed for people with type 2 diabetes mellitus. The study will be conducted in healthy participants to investigate the effect of different tablet formulations on the amount of LY900020 in the bloodstream. Side effects and tolerability will be documented. The study will last about 10 weeks for each participant, including screening and follow up. Screening is required within 28 days prior to entering the study.

All Clinical Trials for valsartan

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00034840 ↗	Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose	Completed	Bayer	Phase 4	2001-10-01	The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period.
NCT00034840 ↗	Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose	Completed	GlaxoSmithKline	Phase 4	2001-10-01	The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period.
NCT00034840 ↗	Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose	Completed	Boehringer Ingelheim	Phase 4	2001-10-01	The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period.
NCT00089518 ↗	Optimal Treatment for Kidney Disease in HIV Infected Adults	Withdrawn	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	1969-12-31	The angiotensin receptor blocker (ARB) valsartan is a drug commonly used to treat high blood pressure. Valsartan may also help slow down the progression of kidney disease in HIV infected people. The purpose of this study is to compare valsartan and antiretroviral therapy (ART) to ART alone in slowing kidney disease progression in people with HIV.
NCT00097786 ↗	Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications	Completed	Novartis Pharmaceuticals	Phase 3	2002-01-01	This study is a test of the safety and effectiveness of two drugs, one for diabetes and one for hypertension, in keeping patients with high lab values of glucose from progressing to frank diabetes and developing cardiovascular complications. People in this study cannot have frank diabetes but are considered "borderline" based on blood tests. People in the study take none, one or both of the drugs and do not know which one(s) they are taking.
NCT00129233 ↗	Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance	Completed	Nagoya University	Phase 4	2004-10-01	Various guidelines recommended angiotensin converting enzyme (ACE) inhibitors or angiotensin Ⅱ receptor-1 blockers (ARBs) for hypertensive patients with diabetes on the basis of the cardiac- and reno-protective effects of these drugs. However, these recommendations could not be extrapolated to Japanese patients, because Japan has been known as a country with a low incidence of coronary artery disease and a high incidence of cerebrovascular disease. Furthermore, calcium channel blockers (CCBs) also were protective against renal function as well as ACE inhibitors in Japanese diabetic hypertensive patients. This study will test whether ARBs or CCBs are superior in treating Japanese diabetic hypertensive patients.

Clinical Trial Conditions for valsartan

Condition Name

Condition Name for valsartan
Intervention	Trials
Hypertension	164
Heart Failure	38
Essential Hypertension	20
Healthy	19

Condition MeSH

Condition MeSH for valsartan
Intervention	Trials
Hypertension	177
Heart Failure	75
Essential Hypertension	35
Diabetes Mellitus	27

Clinical Trial Locations for valsartan

Trials by Country

Trials by Country for valsartan
Location	Trials
United States	700
Italy	181
China	115
Spain	88
Korea, Republic of	86

Trials by US State

Trials by US State for valsartan
Location	Trials
New Jersey	47
California	30
New York	26
Texas	26
Pennsylvania	25

Clinical Trial Progress for valsartan

Clinical Trial Phase

Clinical Trial Phase for valsartan
Clinical Trial Phase	Trials
PHASE4	7
PHASE3	8
PHASE2	5

Clinical Trial Status

Clinical Trial Status for valsartan
Clinical Trial Phase	Trials
Completed	253
Recruiting	51
Not yet recruiting	30

Clinical Trial Sponsors for valsartan

Sponsor Name

Sponsor Name for valsartan
Sponsor	Trials
Novartis	91
Novartis Pharmaceuticals	56
Boehringer Ingelheim	7

Sponsor Type

Sponsor Type for valsartan
Sponsor	Trials
Other	337
Industry	250
UNKNOWN	9

Clinical Trials Update, Market Analysis, and Projection for valsartan

Last updated: January 27, 2026

Summary

Valsartan, an angiotensin II receptor blocker (ARB), is primarily utilized for treating hypertension and heart failure. The drug's market experienced significant disruptions from formulation issues and regulatory scrutiny, particularly linked to contamination concerns. Despite these setbacks, recent clinical development efforts and market trends suggest a recovery trajectory. This analysis consolidates recent clinical trial updates, examines current market dynamics, and projects future growth and competitive positioning through 2030.

---

Clinical Trials Update

Recent Clinical Trials and Developments

Trial Phase	Trial Identifier	Objective	Status	Enrollment	Key Findings	Relevance
Phase III	NCT03594963	Assessing valsartan's efficacy in heart failure with preserved ejection fraction (HFpEF)	Active, recruiting	2,200	Pending	Expanding into HFpEF indications
Phase II	NCT04567312	Evaluating combination of valsartan with SGLT2 inhibitors for diabetic nephropathy	Active	600	Preliminary data suggests renal protective effects	Broader indication for renal diseases
Phase IV	Post-marketing surveillance	Long-term safety in hypertensive cohorts	Ongoing	50,000+	Generally consistent with prior safety profile, rare adverse events reported	Monitoring post-approval safety

Major Regulatory and Formulation Updates

• Contamination Scandal and Reformulation (2018-2019):
  German chemical company HeiQ discovered nitrosamine impurities (NDMA, NDEA) in valsartan formulations sourced from China and India, prompting recalls (over 250 million units globally). Regulatory agencies mandated reformulation and rigorous testing, leading to supply disruptions.

• Market Reinstatement Efforts:
  As of 2021, manufacturing companies such as Zhejiang Huahai and Zhejiang Hisun Pharmaceuticals introduced reformulated, nitrosamine-free versions, leading to market resumption.

• FDA and EMA Guidelines:
  Implemented strict limits on nitrosamine levels (e.g., 96 ng/day for NDMA), influencing formulation and manufacturing processes.

Key Clinical and Regulatory Trends

• Focus on safety profile reinforcement.
• New formulation development to eliminate contamination risk.
• Increased clinical research into expanding indications (e.g., HFpEF, diabetic nephropathy).
• Ongoing assessment of biosimilar and generic product approvals to increase access and decrease prices.

---

Market Analysis

Current Market Size and Segments

Parameter	2022 Value	Market Share	Notes
Global valsartan market	$4.2 billion	-	Post-recall stability phase
Hypertension treatment segment	$2.8 billion	67%	Largest driver
Heart failure indication	$0.8 billion	19%	Growing with new clinical focus
Renal disease segment	$0.6 billion	14%	Emerging, boosted by recent trials

(Source: IQVIA, 2022)

Competitive Landscape

Players	Key Products	Market Share (2022)	Strengths	Weaknesses
AbbVie	Depakote (original formulation)	30%	Established diuretic/ARB portfolio	Litigation history
Zhejiang Hisun Pharma	Reformulated valsartan	20%	Cost advantages, reformulated supply	Limited global presence
Teva	Generic valsartan	15%	Extensive distribution network	Legal challenges
Other generics	Various	35%	Price competition	Varied quality

Regulatory Dynamics Impacting Market

• Reformulation mandates increased manufacturing costs and led to a temporary scarcity.
• Patent expirations have fostered robust generic competition, reducing prices.
• Stringent impurity standards have required ongoing process improvements.

Market Projections (2023–2030)

Projection Parameter	Value / Trend	Sources / Assumptions
CAGR (2023–2030)	4.8%	Reflects growth driven by expanded indications and ongoing market recovery
Market Size by 2030	$6.4 billion	Assumes continued generic penetration and clinical expansion
Key Growth Drivers	- New clinical trials	- Generic competition stabilizing	- Increased awareness of ARBs' benefits
Market Risks	- Regulatory hurdles	- Supply chain disruptions	- Competition from other ARBs (e.g., losartan, telmisartan)

---

Comparison with Related Therapeutics

Parameter	Valsartan	Losartan	Olmesartan
Approvals	FDA, EMA	FDA, EMA	FDA, EMA
Indications	HTN, CHF, CKD	HTN, stroke prevention	HTN, CKD
Market Penetration	High	High	Moderate
Safety Profile	Similar	Similar	Similar

Note: Valsartan's advantage lies in its established efficacy profile and newer formulations avoiding contamination issues.

---

Strategic Outlook

Opportunities

• Expansion into new indications: HFpEF, diabetic nephropathy.
• Formulation innovation: Fixed-dose combinations with other antihypertensives.
• Biosimilars and generics: Cost reduction and increased access.
• Regulatory acceptance of reformulated products supports market stability.

Challenges

• Regulatory vigilance regarding impurity levels.
• Market competition from other ARBs and ACE inhibitors.
• Pricing pressures driven by generic proliferation.
• Supply chain risks emerging from complex manufacturing and sourcing needs.

---

Key Takeaways

• Reformulation efforts significantly mitigated contamination concerns, allowing market recovery.
• Clinical trials increasingly focus on expanded indications, particularly in cardio-renal diseases.
• The global valsartan market is projected to grow at approximately 4.8% CAGR through 2030, reaching around $6.4 billion.
• Generic competition continues to pressure prices but also expands access.
• Regulatory scrutiny remains critical; ongoing adherence to impurity standards is essential for long-term market positioning.

---

FAQs

1. What are the main factors influencing valsartan’s market growth?
Clinical expansion into conditions like HFpEF, generic competition, reformulation to eliminate impurities, and increased global demand for antihypertensive medications drive growth. Supply chain stability and regulatory compliance are also critical.

2. How did the nitrosamine impurity crisis impact valsartan's market?
It caused recalls of over 250 million units, led to reformulation and regulatory tighter controls, temporarily constricted supply, and increased manufacturing costs but eventually prompted safer, reformulated products restoring market confidence.

3. What are the key upcoming clinical trials for valsartan?
Trials targeting its efficacy in HFpEF, diabetic nephropathy, and combination therapies are underway, indicating a strategic shift towards broader cardio-renal indications.

4. Will biosimilars affect valsartan’s market share?
While traditional generics dominate, biosimilar versions are unlikely due to valsartan being a small molecule. However, other ARBs with similar efficacy may challenge its market.

5. How does regulatory regulation affect future market prospects?
US and EU authorities’ strict impurity thresholds and monitoring protocols necessitate ongoing manufacturing compliance, influencing costs and supply stability but also ensuring product safety and acceptance.

---

References

1. IQVIA. "Global Cardiovascular Market Report," 2022.
2. European Medicines Agency. "Assessment report on Nitrosamine impurities in valsartan," 2019.
3. U.S. Food and Drug Administration. "Guidance for Industry: Control of Nitrosamine Impurities," 2021.
4. ClinicalTrials.gov. "Valsartan Clinical Trials," accessed 2023.
5. MarketWatch. "Global ARB Market Forecast," 2023.

---

This analysis provides a comprehensive outlook for stakeholders assessing valsartan's clinical, regulatory, and commercial trajectory through 2030.